Pancreatic beta and alpha cells are both decreased in patients with fulminant type 1 diabetes: a morphometrical assessment.
OBJECTIVE
We have previously reported that fulminant type 1 diabetes is characterised by an absence of diabetes-related antibodies and a remarkably abrupt onset. However, little is known about the mechanism of beta cell destruction in this diabetes subtype, and to obtain insights into the aetiology of the disease, we investigated residual endocrine cells and the expression of Fas and Fas ligand in fulminant type 1 diabetes.


METHODS
Residual beta and alpha cells were morphologically assessed in pancreatic tissue obtained by biopsy from five patients with recent-onset fulminant type 1 diabetes and five patients with recent-onset typical autoimmune type 1 diabetes. In addition, the expression of Fas and Fas ligand was evaluated by immunohistochemistry.


RESULTS
In fulminant type 1 diabetes, beta and alpha cell areas were decreased significantly, compared with autoimmune type 1 diabetes and control subjects. In contrast, the alpha cell area was not decreased significantly in autoimmune type 1 diabetes, compared with that in control subjects. No Fas expression in islets and Fas ligand expression in CD3(+) cells in the exocrine pancreas were found in the fulminant type 1 diabetic patients who underwent this evaluation.


CONCLUSIONS
Our study showed that beta and alpha cells are damaged in fulminant type 1 diabetes. In addition to the lack of Fas and Fas ligand expression, the results suggest that the mechanism of beta cell destruction in fulminant type 1 diabetes is different from that in autoimmune type 1 diabetes.
Sayama
K
K
Department of Internal Medicine and Molecular Science, Graduate School of Medicine, Osaka University, Suita, Japan.
Imagawa
A
A
Okita
K
K
Uno
S
S
Moriwaki
M
M
Kozawa
J
J
Iwahashi
H
H
Yamagata
K
K
Tamura
S
S
Matsuzawa
Y
Y
Hanafusa
T
T
Miyagawa
J
J
Shimomura
I
I
D000138:Acidosis / Q000378:metabolism; D000328:Adult; D003922:Diabetes Mellitus, Type 1 / Q000473:pathology*; D053222:Fas Ligand Protein; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007515:Islets of Langerhans / Q000378:metabolism / Q000473:pathology*; D007651:Keto Acids / Q000378:metabolism; D007662:Ketosis / Q000378:metabolism; D008297:Male; D008562:Membrane Glycoproteins / Q000096:biosynthesis; D046790:Pancreas, Exocrine / Q000378:metabolism; D019014:fas Receptor / Q000096:biosynthesis
C505661:FASLG protein, human; D053222:Fas Ligand Protein; D007651:Keto Acids; D008562:Membrane Glycoproteins; D019014:fas Receptor